A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

Healthy Volunteer Clinical Trial

Official title:

An Open-Label, 2-Part Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01240226
• Other study ID #: GDC4931g
• Status: Completed
• Phase: Phase 1
• First received: November 10, 2010
• Last updated: March 2, 2017
• Start date: November 2010
• Est. completion date: December 2010

Study information

• Verified date: July 2012
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a single-center, open-label, randomized, 2-part study to determine the relative bioavailability of GDC-0941 capsule and market-image tablet formulations and the effect of ketoconazole on the pharmacokinetics of the GDC-0941 market-image tablet formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria

• Medically healthy as determined by the absence of clinically significant findings in the physical examination, medical history, vital sign measurements, clinical laboratory tests, or 12-lead electrocardiograms (ECGs)

• For female subjects: postmenopausal and without recent history of menorrhea, surgically sterile or using an effective method of contraception such as oral or transdermal contraceptives, double-barrier contraception, intrauterine device, depot progesterone, or implanted contraceptive devices, from Day -1 until 45 days after study drug completion/discharge; female subjects must have a negative pregnancy test at Screening and on Day -1

• For male subjects: sterile or a sterile sexual partner, or agreement to use 2 forms of medically acceptable methods of contraception, one of which is a barrier, and agreement not to donate sperm from Screening throughout the study period and for at least 3 months after the last dose of study drug.

Exclusion Criteria

• History of clinical manifestations of significant metabolic (including type 1 and 2 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, gastrointestinal (including gastric or duodenal ulcers), urological, neurological, or psychiatric disease, or cancer

• History of inflammatory arthritis

• History of symptomatic hypotension

• History of severe physical injury, direct impact trauma, or neurological trauma within a specified timeframe prior to initiation of study treatment

• History of seizure disorders

• History of bipolar or major depressive disorder

• History of stomach or intestinal surgery or resection (except appendectomy, hernia repair, and cholecystectomy)

• History or presence of an abnormal ECG

• History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias

• History of alcoholism, drug abuse, or drug addiction

• Use of any nicotine-containing or nicotine-replacement products within a specified timeframe prior to initiation of study treatment

• Use of medications capable of inhibiting hepatic enzymes within a specified timeframe prior to initiation of study treatment

• Participation in any other investigational drug study in which receipt of an investigational study drug occurred within a specified timeframe prior to initiation of study treatment

• Use of any prescription medications/products including monoamine oxidase inhibitors, thioridazine, pimozide, or antidepressants within a specified timeframe prior to initiation of study treatment (2 weeks for antibiotics) (except hormone-replacement therapy or 2 weeks use of narcotics for pain)

• Any vaccination or immunization within a specified timeframe prior to initiation of study treatment

• Routine use of PPIs or histamine H2-receptor antagonists, or any use of these drugs within a specified timeframe prior to initiation of study treatment

• Known hypersensitivity to ketoconazole or other azole antifungals

• Use of any over-the-counter, nonprescription preparations (including supplements, vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations, tryptophans, and St. John's wort) within a specified timeframe prior to initiation of study treatment

• Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages within a specified timeframe prior to initiation of study treatment

• Donated blood within within a specified timeframe prior to initiation of study treatment

• Received blood products within a specified timeframe prior to initiation of study treatment

Related Conditions & MeSH terms

• Healthy Volunteer

Intervention

Drug:
• GDC-0941
Oral repeating dose
• GDC-0941
Oral repeating dose
• ketoconazole
Oral repeating dose

Locations

Country	Name	City	State
United States	Investigational Site	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence, nature, and severity of adverse events		Through study completion or early study discontinuation
Primary	Pharmacokinetic parameters of GDC-0941 (total exposure, maximum and minimum plasma concentration)		Prior to and after GDC-0941 dosing